PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2020
CASE
AUTH/3442/12/20 GlaxoSmithKline ⭐ Case of the Week

AUTH/3442/12/20: Complainant v GlaxoSmithKline (LinkedIn pipeline trial posts) – No breach

Complaint alleged GSK promoted unlicensed RSV vaccine and Covid-19 antibody treatment to the public via LinkedIn. Panel ruled no breach of Clauses…

2021
CASE
AUTH/3545/7/21 Novo Nordisk

Novo Nordisk breached Clause 5.1 after listing an 0845 number for side-effect reporting on Saxenda patient website without call-cost information (AUTH/3545/7/21)

PMCPA ruled Novo Nordisk breached Clause 5.1 (high standards) after a Saxenda patient webpage listed an 0845 number for adverse event reporting…

2019
CASE
AstraZeneca

AstraZeneca Symbicort Turbu+ package deal: prescribing information missing from HCP-accessible website

Complaint about a Symbicort Turbu+ β€œpackage deal” and Turbu+ website. Panel found no inducement to prescribe, but ruled breach where HCP-accessible package…

2020
CASE
AUTH/3411/10/20 AstraZeneca

AUTH/3411/10/20 & AUTH/3412/10/20: LinkedIn β€˜likes’ brought a US trial post into UK Code scope (Daiichi Sankyo & AstraZeneca)

UK employees β€˜liked’ a US LinkedIn post about a Phase 3 trial for Enhertu. The Panel said the β€˜likes’ proactively disseminated the…

2021
CASE
AUTH/3483/3/21 Eli Lilly

Eli Lilly: UK employees’ LinkedIn β€˜likes’ treated as promotion of an unlicensed medicine (AUTH/3483/3/21)

Six UK-based Lilly staff β€˜liked’ a US corporate LinkedIn post about investigational tirzepatide trial results. PMCPA ruled this proactively disseminated unlicensed promotion…

2021
CASE
AUTH/3560/9/21 Sanofi ⭐ Case of the Week

AUTH/3560/9/21: Anonymous health professional complaint about pressure to sign up to diabetes review service (No breach) – Sanofi

Anonymous nurse alleged a Sanofi account executive pressured them to sign up to a diabetes therapy review service β€œas a favour”. Panel…

2021
CASE
AUTH/3571/10/21 Merck

Merck Serono e-symposium on Pergoveris: IVF references and study slide challenged (AUTH/3571/10/21) – No breach

Complaint alleged off-label promotion linking Pergoveris to IVF and that a study slide lacked key methodological limitations. PMCPA Panel ruled no breach…

2021
CASE
AUTH/3581/11/21 Roche Products

Roche: public disease information on corporate website not certified (AUTH/3581/11/21)

Roche UK hosted disease education pages on roche.co.uk that the Panel said were in scope of the ABPI Code and required certification.…

2021
CASE
AUTH/3591/12/21 Pfizer

Pfizer CEO BBC interview: unqualified comments on vaccinating 5–11s found misleading (AUTH/3591/12/21)

UsForThem complained about a BBC Health article quoting Pfizer’s CEO on vaccinating 5–11s. Appeal Board found breaches for misleading, unsubstantiated, unbalanced public…

2022
CASE
AUTH/3631/4/22 AstraZeneca

AstraZeneca & Daiichi Sankyo: Advisory board contracts lacked clarity on advice sought (AUTH/3631/4/22, AUTH/3636/4/22)

Two companies breached Clause 5.1 after advisors signed contracts for a T-DXd 2L mBC advisory board without sufficient detail on the specific…

2021
CASE
AUTH/3482/3/21 GlaxoSmithKline ⭐ Case of the Week

AUTH/3482/3/21: Complainant v GlaxoSmithKline (LinkedIn post about Nucala) – Out of scope of the ABPI Code

A complaint alleged promotion of Nucala (mepolizumab) on LinkedIn. The PMCPA recorded the case as outwith the scope of the ABPI Code,…

2022
CASE
AUTH/3648/5/22 Novartis Pharmaceuticals UK

Novartis: Entresto virtual meeting and meeting write-up ruled promotional; missing PI and AE reporting (AUTH/3648/5/22)

Novartis-funded HF virtual meeting was deemed promotional despite being classed non-promotional. Meeting write-up promoted Entresto but omitted prescribing info, AE reporting and…

2021
CASE
AbbVie

AbbVie breached ABPI Code over Rinvoq webpages: imagery implied strenuous activity and omitted prominent pregnancy/contraception warnings

PMCPA found AbbVie’s Rinvoq RA/PsA webpages misleading: surfing imagery implied unrealistic outcomes and pages didn’t prominently flag pregnancy contraindication/contraception advice for women…

2022
CASE
AUTH/3685/8/22 Sandoz

Sandoz: Omnitrope cool bag exceeded Β£10 limit and withdrawal not communicated proactively (AUTH/3685/8/22)

Sandoz supplied an Omnitrope cool bag costing Β£13.66 (over the Β£10 limit) and later withdrew it without proactive stakeholder communication. Breaches of…

2022
CASE
AUTH/3716/11/22 Ferring Pharmaceuticals

Ferring Pharmaceuticals: failure to fully withdraw Pentasa leavepiece with incorrect prescribing information (AUTH/3716/11/22)

Ferring confirmed withdrawal of Pentasa material with incorrect dosing info, but a hidden website hyperlink kept the leavepiece accessible for ~11 weeks.…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training